These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 6832389)

  • 21. Possible mechanisms for reduced plasma clearance of diflunisal in rat experimental renal failure.
    Lin JH; Ulm EH; Duggan DE
    J Pharmacol Exp Ther; 1986 Sep; 238(3):978-84. PubMed ID: 3746671
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Furosemide kinetics and dynamics in patients with cirrhosis.
    Villeneuve JP; Verbeeck RK; Wilkinson GR; Branch RA
    Clin Pharmacol Ther; 1986 Jul; 40(1):14-20. PubMed ID: 3720175
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of probenecid on the distribution and elimination of ciprofloxacin in humans.
    Jaehde U; Sörgel F; Reiter A; Sigl G; Naber KG; Schunack W
    Clin Pharmacol Ther; 1995 Nov; 58(5):532-41. PubMed ID: 7586947
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Influence of probenecid and spironolactone on furosemide kinetics and dynamics in man.
    Homeida M; Roberts C; Branch RA
    Clin Pharmacol Ther; 1977 Oct; 22(4):402-9. PubMed ID: 902453
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of probenecid on furosemide kinetics and natriuresis in man.
    Honari J; Blair AD; Cutler RE
    Clin Pharmacol Ther; 1977 Oct; 22(4):395-401. PubMed ID: 902452
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Disposition kinetics of furosemide in dogs.
    El-Sayed MG; Atef M; El-Gendi AY; Youssef SA
    Arch Int Pharmacodyn Ther; 1981 Sep; 253(1):4-10. PubMed ID: 7325754
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Plasma binding and disposition of furosemide in the nephrotic syndrome and in uremia.
    Rane A; Villeneuve JP; Stone WJ; Nies AS; Wilkinson GR; Branch RA
    Clin Pharmacol Ther; 1978 Aug; 24(2):199-207. PubMed ID: 679597
    [No Abstract]   [Full Text] [Related]  

  • 28. Nonrenal clearance of furosemide as a cause of diuretic response variability in the rat.
    Lambert C; Caillé G; du Souich P
    J Pharmacol Exp Ther; 1982 Jul; 222(1):232-6. PubMed ID: 7086701
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Renal secretion of [35-S]furosemide and depression by albumin binding.
    Bowman RH
    Am J Physiol; 1975 Jul; 229(1):93-8. PubMed ID: 1147061
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Impaired plasma protein binding of furosemide in nephrotic syndrome and uremia].
    Takahashi F
    Nihon Jinzo Gakkai Shi; 1982 Jun; 24(6):665-80. PubMed ID: 7176178
    [No Abstract]   [Full Text] [Related]  

  • 31. Plasma and urinary kinetics of furosemide in newborn infants.
    Tuck S; Morselli P; Broquaire M; Vert P
    J Pediatr; 1983 Sep; 103(3):481-5. PubMed ID: 6886918
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect on nephrotic syndrome on absorption and disposition of prednisolone in children.
    Rocci ML; Assael BM; Appiani AC; Edefonti A; Jusko WJ
    Int J Pediatr Nephrol; 1982 Sep; 3(3):159-66. PubMed ID: 7141787
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Elimination of furosemide in healthy subjects and in those with renal failure.
    Beermann B; Dalén E; Lindström B
    Clin Pharmacol Ther; 1977 Jul; 22(1):70-8. PubMed ID: 872498
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Furosemide disposition in cirrhosis.
    Verbeeck RK; Patwardhan RV; Villeneuve JP; Wilkinson GR; Branch RA
    Clin Pharmacol Ther; 1982 Jun; 31(6):719-25. PubMed ID: 7075120
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increased nonrenal clearance and increased diuretic efficiency of furosemide in cystic fibrosis.
    Alván G; Beermann B; Hjelte L; Lind M; Lindholm A; Strandvik B
    Clin Pharmacol Ther; 1988 Oct; 44(4):436-41. PubMed ID: 3168395
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Binding inhibitors restore furosemide potency in tubule fluid containing albumin.
    Kirchner KA; Voelker JR; Brater DC
    Kidney Int; 1991 Sep; 40(3):418-24. PubMed ID: 1724020
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Furosemide kinetics and dynamics after kidney transplant.
    Smith DE; Gambertoglio JG; Vincenti F; Benet LZ
    Clin Pharmacol Ther; 1981 Jul; 30(1):105-13. PubMed ID: 7016396
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics and disposition of L-692,429. A novel nonpeptidyl growth hormone secretagogue in preclinical species.
    Leung KH; Cohn DA; Miller RR; Doss GA; Stearns RA; Simpson RE; Feeney WP; Chiu SH
    Drug Metab Dispos; 1996 Jul; 24(7):753-60. PubMed ID: 8818572
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Disposition of L-738,167, a potent and long-acting fibrinogen receptor antagonist, in dogs. Dose-dependent pharmacokinetics.
    Prueksaritanont T; Gorham LM; Naue JA; Hamill TG; Askew BC; Vyas KP
    Drug Metab Dispos; 1997 Mar; 25(3):355-61. PubMed ID: 9172954
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Probenecid inhibits the renal clearance of frusemide and its acyl glucuronide.
    Vree TB; van den Biggelaar-Martea M; Verwey-van Wissen CP
    Br J Clin Pharmacol; 1995 Jun; 39(6):692-5. PubMed ID: 7654491
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.